Form 8-K TITAN PHARMACEUTICALS For: Nov 10

�

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C.� 20549

�

FORM 8-K

CURRENT REPORT

�

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

�

Date of Report (Date of Earliest Event Reported): November 10, 2014

�

Titan Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

�

Delaware

(State or other jurisdiction of incorporation)

�

0-27436	94-3171940
(Commission File Number)	(IRS Employer Identification No.)

�

400 Oyster Point Blvd., Suite 505, South San Francisco, CA 94080

---

(Address of principal executive offices and zip code)

650-244-4990�

�

�

---

(Registrant's telephone number including area code)

�

�

---

(Registrant's former name or former address, if changed since last report)

�

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

�

�

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

�

�

�

Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12(b))

�

�

�

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

�

�

�

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

�

�

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

�

On November 10, 2014, Titan Pharmaceuticals, Inc. (the “Company”) announced the appointment of Joseph A. Akers and James R. McNab, Jr. to the Company’s Board of Directors (the “Board”).

�

From 1970 until his retirement in 2007, Mr. Akers (68) was employed in various capacities by Bayer Corporation, Bayer Healthcare and certain related entities, including as president of the Hematology/Cardiology Business Unit from 2004 to 2007, president and chief executive officer of Bayer Business and Corporate Services from July 2002 through 2003 and executive vice president and chief administrative and financial officer from 1999 to July 2002. Mr. Akers received a B.S. in marketing and an M.B.A. in finance from the University of California at Berkeley.

�

Since 1998, Mr. McNab (70) has served as chief executive officer and chairman of Palmetto Pharmaceuticals, Inc., a privately-held drug discovery company he founded. He has been a chairman of the board of directors of Curis, Inc. (Nasdaq:CRIS), an oncology focused biotechnology company, since May 2002. Since 2009, Mr. McNab has served as executive chairman of FirstString Research, Inc., a privately-held biopharmaceutical company, and as chief executive officer of Halimed Pharmaceuticals, Inc., a privately-held drug discovery company, and has served as a member of its board of directors since 2010. Mr. McNab has co-founded several privately-held companies, including Sontra Medical Corporation, a drug delivery company, and Parker Medical Associates, a manufacturer and worldwide supplier of orthopedic and sports-related products. He received a B.A. in economics from Davidson College and an M.B.A. from the University of North Carolina at Chapel Hill.

�

The Board appointed Mr. Akers to serve as a member of the audit committee and Mr. McNab to serve as a member of the nominating and corporate governance committee.

�

In connection with their appoint to the Board, each of Messrs. Akers and McNab were granted options to purchase 25,000 shares of the Company’s common stock at an exercise price equal to fair market value on the grant date, which options vest in full on the first anniversary of the date of grant.

�

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

�

Item 9.01.

Financial Statement and Exhibits.

�

(d)� Exhibits.

�

Exhibit No.	�	Description
�	�	�
99.1	�	Press Release dated November 11, 2014

�

�

SIGNATURES

�

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.�(

�

�	TITAN PHARMACEUTICALS, INC.		�
�	�		�
�	By:	/s/ Sunil Bhonsle	�
�	Name:	Sunil Bhonsle	�
�	Title:	President	�

Dated: November 12, 2014

�

�

Exhibit 99.1

�

�

TITAN PHARMACEUTICALS APPOINTS TWO NEW BOARD MEMBERS

�

South San Francisco, CA – Nov. 11, 2014 – Titan Pharmaceuticals, Inc. (TTNP.OB) announced today that it has appointed life sciences industry veterans Joseph A. Akers and James McNab Jr. to its board of directors. Mr. Akers, a former Bayer HealthCare executive, and Mr. McNab, chairman and co-founder of Curis, Inc., together bring extensive product development, commercialization, finance and corporate governance experience to Titan.

�

“We are extremely pleased to welcome Mr. Akers and Mr. McNab to our board of directors,” said Titan Executive Chairman Marc Rubin, M.D. “Their expertise and skills will be valuable assets to Titan in assisting us with corporate development as we expand our portfolio of product candidates based on our ProNeura™ long-term drug delivery technology, and as we prepare to resubmit the New Drug Application for Probuphine� for the maintenance treatment of opioid dependence next year.”

�

Mr. Akers brings to Titan extensive executive and financial experience. As president of Bayer’s hematology/cardiology business, he oversaw the core of Bayer’s specialty pharmaceuticals development, with significant products in hematology and specialty cardiology. Mr. Akers also served as president and CEO of Bayer Business and Corporate Services and held numerous other financial and executive positions during his 37-year career with the company. He has served on the boards of Haemacure Corp., POINT Biomedical Corp. and Schein Pharmaceuticals. As a Titan board member, he will serve on the board’s audit committee.

�

“With the rapid growth in the aging population globally, new treatments that can improve health and quality of life for patients suffering from chronic diseases are increasingly needed,” Mr. Akers said. “Having validated the ProNeura platform in Probuphine, Titan is in the position to build additional value for the company based on this innovative technology and I’m eager to contribute.”

�

Mr. McNab, an entrepreneur experienced in building and growing companies, brings to Titan extensive corporate development experience. He is co-founder and chairman of Curis, a publicly traded oncology company that partnered with Roche to develop and commercialize a first-in-class hedgehog inhibitor for the treatment of advanced basal cell carcinoma. Mr. McNab serves as CEO and chairman of Palmetto Pharmaceuticals, executive chairman of FirstString Research Inc., and chairman of JT Pharmaceuticals. Previously Mr. McNab was founder of Vidus Ocular, a glaucoma device company that was sold to OPKO Health, and co-founder of Sontra Medical, which developed a medical low frequency ultrasound device from Massachusetts Institute of Technology that was sold to Echo Therapeutics. Mr. McNab will serve on the board’s corporate governance and nominating committee.

�

�

“I’m very pleased to join Titan’s board of directors at such an important time,” Mr. McNab said. “The ProNeura drug delivery platform has the potential to transform the way select chronic diseases are treated, and I look forward to working with the Titan board and management to advance new product candidates through preclinical and clinical development.”

�

About Titan Pharmaceuticals

Titan Pharmaceuticals Inc. (TTNP.OB), based in South San Francisco, CA, is a specialty pharmaceutical company developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company’s lead product candidate is Probuphine�, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence. Probuphine employs Titan’s proprietary drug delivery system ProNeura™, which is capable of delivering sustained, consistent levels of medication for six months or longer. Titan has granted North American commercial rights for Probuphine to Braeburn Pharmaceuticals. If approved, Probuphine would be the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions, such as Parkinson’s disease, where maintaining consistent blood levels of a dopamine agonist may benefit the patient and improve medical outcomes. For more information about Titan, please visit www.titanpharm.com.

�

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our product development programs and any other statements that are not historical facts. Such statements involve risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from management's current expectations include those risks and uncertainties relating to the regulatory approval process, the development, testing, production and marketing of our drug candidates, patent and intellectual property matters and strategic agreements and relationships.� We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

�

CONTACT:

Titan Pharmaceuticals, Inc.	Media
Sunil Bhonsle, 650-244-4990	Susan Thomas, 619-540-9195
President	[email protected]

�

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Dimensional Fund Advisors Ltd. : Form 8.3 - QUANEX BUILDING PRODUCTS - Ordinary Shares
• Green Energy Park Raises 30 million US Dollars in Initial Equity Funding to Accelerate the Energy Transition and to Build One of the Largest Renewable Hydrogen Production and Export Terminal Facilitie
• SKEL fjárfestingafélag hf.: Trading statement Q1 2024